Active delivery assessment
What is Active delivery assessment?
Comparative availability or localisation from different carriers; scope versus absorption/distribution must be defined.
Why do you need this service?
Active-delivery assessment compares availability or localisation of a defined analyte from different carriers. Agree whether the question concerns release, skin deposition or permeation before selecting the measurement.
Be the first company on this service page
No published company profiles are linked to Active delivery assessment or its more specific services yet. Explore the service categories or add an explicitly supported capability to your company profile.
Active delivery assessment
This service evaluates a delivery approach against a defined objective, such as retaining an ingredient near the surface or increasing its availability within a selected skin compartment. It is broader than measuring receptor-fluid permeation alone, but the exact endpoints must be agreed before testing.
Tracking the ingredient
- Diffusion studies with selective analyte quantification
- Tape stripping for stratum-corneum deposition
- Tissue separation and extraction for specified compartments
- Confocal or fluorescence imaging where labeling and resolution are suitable
A fluorescent label may not follow the intact ingredient or carrier throughout the study. Analytical confirmation and appropriate controls are needed before an image is interpreted as proof of delivery.
Availability versus activity
Measuring an ingredient in a tissue extract shows recovery under the test conditions, not automatically biological availability or maintained activity. If the project also examines antioxidant function, enzyme activity or another biological endpoint, the assay must be relevant and distinguish ingredient effects from matrix interference.
Comparisons with an unencapsulated ingredient or alternative vehicle can help evaluate a carrier’s contribution. Reports should state what was measured, where and when, and identify recovery and model limitations. Delivery evidence can guide formulation choices but does not on its own prove clinical performance or protection of every encapsulated ingredient.
Comparing carrier-dependent delivery
Provide the formulations and the active to be followed so the analytical method can distinguish it from the vehicle and other ingredients. A botanical mixture needs a defined analyte or justified marker rather than an assumed measurement of the entire extract.
Tape stripping can assess stratum-corneum deposition. Deeper localisation requires an appropriate additional tissue or imaging method, with any label shown to represent the analyte of interest. A diffusion-cell receptor profile answers a different question from a depth map.
Compare measured recovery under defined conditions instead of assuming a delivery target that applies to most actives. Greater delivery is not automatically a benefit and does not establish clinical efficacy or safety. Changes in molecular weight involve the ingredient identity, not merely adjustment of its vehicle.
Choose cosmetic penetration and delivery studies by your question: skin uptake, layer distribution, comparative delivery or release over time. Explore another Skin Absorption Studies page on cosmetic-labs.com.